A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular ...
Jun 8, 2016
0
5
Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis ...
Apr 15, 2016
0
3
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, ...
Apr 15, 2016
0
0
The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small-cell lung cancer (NSCLC), according to a late-breaking ...
Apr 14, 2016
0
0
Researchers have identified a link between the expression of a cancer-related gene and cell-surface molecules that protect tumors from the immune system.
Mar 10, 2016
0
228
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery. The finding comes from a ...
Mar 10, 2016
0
28
(HealthDay)—Cola intake leads to a clinically relevant and statistically significant increase in the bioavailability of erlotinib during esomeprazole treatment, according to a study published online Feb. 8 in the Journal ...
Feb 10, 2016
0
1
(HealthDay)—For patients with non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, erlotinib is active, and treatment beyond progression is feasible and may delay salvage ...
Jan 5, 2016
0
4
Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report at the first ESMO Asia 2015 Congress in Singapore.
Dec 21, 2015
0
1
Patients younger than 50 diagnosed with non-small-cell lung cancer (NSCLC) had a higher likelihood of having a targetable genomic alteration for which therapies exist, according to an article published online by JAMA Oncology.
Dec 17, 2015
0
0
